Pennsylvania

Fetterman, Casey slam federal judge’s ruling against abortion medication

Pennlive.Com
By Pennlive.Com
2 Min Read April 9, 2023 | 3 years Ago
Go Ad-Free today

Pennsylvania’s Democratic U.S. Sens. John Fetterman and Bob Casey did not mince words when responding to Friday’s ruling by a federal judge in Texas halting the approval of an abortion medication.

“This ruling by a hard-right Trump appointed judge is simply bull(expletive),” Fetterman said in a statement released Saturday morning.

“An ideological judge overturning an FDA decision is dangerous, unprecedented, and extreme,” Casey said in a Saturday morning tweet. “This ruling is a back-door attempt by right-wing politicians to implement a nationwide abortion ban.”

Judge Matthew Kacsmaryk, a longtime abortion rights opponent, stopped the U.S. Food and Drug Administration’s approval of mifepristone, one of two drugs used for its medication abortion regimen. Mifepristone has been available for more than 20 years.

Kacsmaryk wrote in his opinion that the drug’s improper approval violated federal law.

Abortion rights advocates bristled against the ruling, saying it was simply a way for abortion opponents to ban access nationally after the U.S. Supreme Court overturned federal abortion rights last year and returned the decision to states.

“This is nothing more than another attempt by the GOP to take away the rights of women and implement a nationwide abortion ban,” Fetterman said. “Mifepristone remains safe and legal in Pennsylvania. We will fight this, and we will win.”

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options